Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Zubrod Performance Status 0 or 1~* Adequate bone marrow, liver and renal function as assessed by the following:~  * Hemoglobin \> 9.0 g/dl~ * Absolute neutrophil count (ANC) \> 1,500/mm3~ * Platelet count \> 100,000/mm3~ * Total bilirubin \< 1.5 times institutional upper limit of normal (ULN)~ * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 times the institutional ULN~ * Creatinine \< 1.5 times institutional ULN~* Histologically or cytologically confirmed renal cell carcinoma, which is metastatic, unresectable or recurrent.~* Life expectancy \> 6 months~* Local recurrence or progression of primary lesion or progression, or symptomatic progression in extra-cranial, extra-pulmonary metastases while on sorafenib~* Measurable disease~* Bone metastases must have a tissue component measurable by imaging.~* No untreated brain metastases~* Resolution of pre-existing toxicity from prior therapy excluding alopecia and taste alteration.~* Willingness and ability to comply with continuing sorafenib, visits, treatment plans, laboratory tests and study procedures.~* All treated lesions must comply with SBRT dose constraints~* More than 28 days since any prior systemic or local therapy for this cancer, including investigational agents and surgical procedures exclusive of sorafenib~* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control)~* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.~* Ability to understand and the willingness to sign a written informed consent.~* Prothrombin time(PT) and partial thromboplastin time (PTT) within normal limits.~Exclusion Criteria:~* Lesion in remaining (solo) kidney~* Contraindications to radiotherapy or prior radiotherapy overlapping current site(s) of disease.~* Cardiac disease: Congestive heart failure. Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.~* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.~* Uncontrolled hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management.~* Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.~* Active clinically serious infection~* Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.~* Pulmonary hemorrhage/bleeding event within 4 weeks of first dose of study drug.~* Any other hemorrhage/bleeding event within 4 weeks of first dose of study drug.~* Serious non-healing wound, ulcer, or bone fracture.~* Evidence or history of bleeding problems~* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.~* Use of St. John's Wort or rifampin (rifampicin).~* Known or suspected allergy to sorafenib or any agent given in the course of this trial.~* Any condition that impairs patient's ability to swallow whole pills.~* Any malabsorption problem.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).